Emergent BioSolutions Inc. (0IGA.L)
USD 8.5
(-3.22%)
USD 8.5
(-3.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 877.5 Million USD | -37.58% |
| 2022 | 1.4 Billion USD | 67.16% |
| 2021 | 841 Million USD | -3.86% |
| 2020 | 874.8 Million USD | 7.83% |
| 2019 | 811.3 Million USD | 2.1% |
| 2018 | 794.6 Million USD | 5804.73% |
| 2017 | 13.45 Million USD | -94.98% |
| 2016 | 268.09 Million USD | 5.97% |
| 2015 | 253 Million USD | 0.8% |
| 2014 | 251 Million USD | 304.84% |
| 2013 | 62 Million USD | -1.23% |
| 2012 | 62.77 Million USD | 5.58% |
| 2011 | 59.45 Million USD | 25.36% |
| 2010 | 47.42 Million USD | -27.83% |
| 2009 | 65.71 Million USD | 14.93% |
| 2008 | 57.18 Million USD | -1.3% |
| 2007 | 57.93 Million USD | 35.45% |
| 2006 | 42.77 Million USD | 259.12% |
| 2005 | 11.91 Million USD | -7.44% |
| 2004 | 12.86 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 33.8 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 876.8 Million USD | -4.92% |
| 2024 Q1 | 922.2 Million USD | 5.09% |
| 2023 Q2 | 903.2 Million USD | -35.41% |
| 2023 Q4 | 877.5 Million USD | 112.16% |
| 2023 FY | 877.5 Million USD | -37.58% |
| 2023 Q1 | 1.39 Billion USD | -0.53% |
| 2023 Q3 | 413.6 Million USD | -54.21% |
| 2022 FY | 1.4 Billion USD | 67.16% |
| 2022 Q4 | 1.4 Billion USD | 33.47% |
| 2022 Q2 | 825.2 Million USD | -0.95% |
| 2022 Q3 | 1.05 Billion USD | 27.64% |
| 2022 Q1 | 833.1 Million USD | -0.94% |
| 2021 FY | 841 Million USD | -3.86% |
| 2021 Q1 | 859.1 Million USD | -1.79% |
| 2021 Q2 | 854 Million USD | -0.59% |
| 2021 Q3 | 848.9 Million USD | -0.6% |
| 2021 Q4 | 841 Million USD | -0.93% |
| 2020 Q1 | 789.2 Million USD | -2.72% |
| 2020 FY | 874.8 Million USD | 7.83% |
| 2020 Q4 | 874.8 Million USD | -0.52% |
| 2020 Q3 | 879.4 Million USD | 11.71% |
| 2020 Q2 | 787.2 Million USD | -0.25% |
| 2019 Q3 | 823.4 Million USD | -2.03% |
| 2019 Q4 | 811.3 Million USD | -1.47% |
| 2019 Q2 | 840.5 Million USD | 13.2% |
| 2019 FY | 811.3 Million USD | 2.1% |
| 2019 Q1 | 742.5 Million USD | -6.56% |
| 2018 Q2 | 13.48 Million USD | 0.1% |
| 2018 Q1 | 13.46 Million USD | 0.09% |
| 2018 FY | 794.6 Million USD | 5804.73% |
| 2018 Q3 | 13.49 Million USD | 0.1% |
| 2018 Q4 | 794.6 Million USD | 5788.11% |
| 2017 FY | 13.45 Million USD | -94.98% |
| 2017 Q4 | 13.45 Million USD | -94.6% |
| 2017 Q3 | 248.99 Million USD | 0.12% |
| 2017 Q2 | 248.69 Million USD | 0.12% |
| 2017 Q1 | 248.39 Million USD | -7.35% |
| 2016 Q4 | 268.09 Million USD | 0.11% |
| 2016 FY | 268.09 Million USD | 5.97% |
| 2016 Q1 | 247.19 Million USD | -2.3% |
| 2016 Q2 | 247.39 Million USD | 0.08% |
| 2016 Q3 | 267.79 Million USD | 8.25% |
| 2015 Q3 | 253 Million USD | 0.0% |
| 2015 Q1 | 251 Million USD | 0.0% |
| 2015 Q4 | 253 Million USD | 0.0% |
| 2015 FY | 253 Million USD | 0.8% |
| 2015 Q2 | 253 Million USD | 0.8% |
| 2014 Q2 | 251 Million USD | 0.0% |
| 2014 Q1 | 251 Million USD | 304.84% |
| 2014 FY | 251 Million USD | 304.84% |
| 2014 Q4 | 251 Million USD | 0.0% |
| 2014 Q3 | 251 Million USD | 0.0% |
| 2013 Q4 | 62 Million USD | 4.34% |
| 2013 Q1 | 61.65 Million USD | -1.78% |
| 2013 Q2 | 60.53 Million USD | -1.81% |
| 2013 FY | 62 Million USD | -1.23% |
| 2013 Q3 | 59.42 Million USD | -1.85% |
| 2012 FY | 62.77 Million USD | 5.58% |
| 2012 Q3 | 63.01 Million USD | 1.31% |
| 2012 Q2 | 62.19 Million USD | 2.18% |
| 2012 Q1 | 60.87 Million USD | 2.39% |
| 2012 Q4 | 62.77 Million USD | -0.38% |
| 2011 FY | 59.45 Million USD | 25.36% |
| 2011 Q4 | 59.45 Million USD | 10.52% |
| 2011 Q3 | 53.79 Million USD | 36.87% |
| 2011 Q2 | 39.3 Million USD | -15.63% |
| 2011 Q1 | 46.58 Million USD | -1.78% |
| 2010 Q4 | 47.42 Million USD | -1.73% |
| 2010 Q1 | 64.96 Million USD | -1.15% |
| 2010 Q2 | 49.09 Million USD | -24.42% |
| 2010 Q3 | 48.26 Million USD | -1.7% |
| 2010 FY | 47.42 Million USD | -27.83% |
| 2009 FY | 65.71 Million USD | 14.93% |
| 2009 Q4 | 65.71 Million USD | 66.01% |
| 2009 Q3 | 39.58 Million USD | -28.75% |
| 2009 Q2 | 55.55 Million USD | -1.71% |
| 2009 Q1 | 56.52 Million USD | -1.15% |
| 2008 Q2 | 59.31 Million USD | -1.52% |
| 2008 Q4 | 57.18 Million USD | -2.07% |
| 2008 Q1 | 60.22 Million USD | 3.96% |
| 2008 FY | 57.18 Million USD | -1.3% |
| 2008 Q3 | 58.39 Million USD | -1.55% |
| 2007 Q3 | 46.97 Million USD | 44.01% |
| 2007 Q2 | 32.61 Million USD | -2.3% |
| 2007 Q4 | 57.93 Million USD | 23.33% |
| 2007 Q1 | 33.38 Million USD | -21.95% |
| 2007 FY | 57.93 Million USD | 35.45% |
| 2006 Q4 | 42.77 Million USD | 17.27% |
| 2006 FY | 42.77 Million USD | 259.12% |
| 2006 Q3 | 36.47 Million USD | 0.0% |
| 2005 Q4 | 11.91 Million USD | 0.0% |
| 2005 FY | 11.91 Million USD | -7.44% |
| 2004 FY | 12.86 Million USD | 0.0% |
| 2004 Q4 | 12.86 Million USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 31.6 Million USD | 0.0% |
| 2001 FY | 33.8 Million USD | 0.0% |
| 2000 Q4 | 957.3 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -2301.741% |
| Dynavax Technologies Corporation | 256.91 Million USD | -241.554% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -2013.083% |
| Perrigo Company plc | 4.07 Billion USD | 78.458% |
| Illumina, Inc. | 2.26 Billion USD | 61.207% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 97.487% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -87650.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 90.815% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 93.834% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -405.027% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 67.535% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -3151.204% |
| Waters Corporation | 2.35 Billion USD | 62.747% |
| Biogen Inc. | 7.33 Billion USD | 88.042% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -2202.908% |
| Evolus, Inc. | 126.54 Million USD | -593.424% |
| Adicet Bio, Inc. | 17.7 Million USD | -4856.787% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -1932.803% |
| bluebird bio, Inc. | 330.32 Million USD | -165.647% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -62.216% |
| FibroGen, Inc. | 170.45 Million USD | -414.799% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 67.916% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -4101.735% |
| Homology Medicines, Inc. | 44.05 Million USD | -1891.874% |
| Geron Corporation | 85.89 Million USD | -921.549% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 63.407% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -97.165% |
| Myriad Genetics, Inc. | 145 Million USD | -505.172% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -69542.857% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -660.755% |
| Zoetis Inc. | 6.8 Billion USD | 87.101% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -19834.121% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 59.521% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 22.611% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -8.548% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -2315.825% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 39.63% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -1416.277% |
| Verastem, Inc. | 41.55 Million USD | -2011.558% |
| Nektar Therapeutics | 230.4 Million USD | -280.858% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -370.833% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -28445.869% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 37.178% |
| OPKO Health, Inc. | 326.56 Million USD | -168.707% |
| Exelixis, Inc. | 189.94 Million USD | -361.978% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -104.832% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -581025.828% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -533.991% |
| Imunon, Inc. | 1.13 Million USD | -76921.451% |
| Blueprint Medicines Corporation | 774.12 Million USD | -13.354% |
| Insmed Incorporated | 1.2 Billion USD | 27.118% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 41.471% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1439.798% |
| TG Therapeutics, Inc. | 110.79 Million USD | -692.003% |
| Incyte Corporation | 38.28 Million USD | -2191.901% |